---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-024872"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2026-05-21T21:28:23+00:00"
generated_at: "2026-05-21T21:33:41.397973+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma prices $150M public offering of 16.8M shares at $8.94

## Summary
- Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.
- Offering of 16,778,524 shares priced at $8.94 per share; closes May 22, 2026.
- Net proceeds to fund NXC-201 development, working capital, and general corporate purposes.
- Cash runway extended to mid-2028 with existing cash plus offering net proceeds.
- Morgan Stanley leads underwriters; BofA Securities, LifeSci Capital, Mizuho, Needham co-manage.

## SEC filing metadata
- accession: 0001493152-26-024872
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2026-05-21T21:28:23+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315226024872/0001493152-26-024872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315226024872/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-024872
- JSON: https://secwatch.observer/filing/0001493152-26-024872.json
- Plain text: https://secwatch.observer/filing/0001493152-26-024872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.